- Home
- NRC vs CTNM Comparison
NRC vs CTNM Comparison
Compare NRC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- CTNM
- Stock Information
- Founded
- NRC 1981
- CTNM 2009
- Country
- NRC United States
- CTNM United States
- Employees
- NRC N/A
- CTNM N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- CTNM
- Sector
- NRC Health Care
- CTNM
- Exchange
- NRC Nasdaq
- CTNM Nasdaq
- Market Cap
- NRC 426.3M
- CTNM 378.7M
- IPO Year
- NRC N/A
- CTNM 2024
- Fundamental
- Price
- NRC $17.17
- CTNM $13.50
- Analyst Decision
- NRC
- CTNM Strong Buy
- Analyst Count
- NRC 0
- CTNM 4
- Target Price
- NRC N/A
- CTNM $29.25
- AVG Volume (30 Days)
- NRC 114.1K
- CTNM 134.3K
- Earning Date
- NRC 02-11-2025
- CTNM 02-16-2025
- Dividend Yield
- NRC 2.80%
- CTNM N/A
- EPS Growth
- NRC N/A
- CTNM N/A
- EPS
- NRC 1.12
- CTNM N/A
- Revenue
- NRC $144,155,000.00
- CTNM N/A
- Revenue This Year
- NRC N/A
- CTNM N/A
- Revenue Next Year
- NRC N/A
- CTNM N/A
- P/E Ratio
- NRC $15.29
- CTNM N/A
- Revenue Growth
- NRC N/A
- CTNM N/A
- 52 Week Low
- NRC $16.74
- CTNM $12.33
- 52 Week High
- NRC $42.18
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- NRC 35.82
- CTNM N/A
- Support Level
- NRC $16.74
- CTNM N/A
- Resistance Level
- NRC $18.31
- CTNM N/A
- Average True Range (ATR)
- NRC 0.80
- CTNM 0.00
- MACD
- NRC -0.22
- CTNM 0.00
- Stochastic Oscillator
- NRC 13.46
- CTNM 0.00
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.